Healthcare
Caribou Biosciences, Inc.(CRBU)
Live Price
Offline$1.64
+0.00% today
1Y Change
+15.49%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $190.00M
- Revenue Growth
- +11.7%
- EPS Growth
- +3.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Caribou Biosciences, Inc. (CRBU) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $1.64 and up 15.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +11.7%, EPS growth of +3.6%, a dividend yield of 0.0%. What stands out right now is revenue +11.7%, EPS +3.6%, free cash flow +22.4% with operating margin -1329.4% and ROIC -95.1%. Valuation already assumes a fairly strong business story at price/sales 16.8. Stock Foundry combines CRBU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.7% vs +7.6% peer median
Operating Margin
Below sector median
-1329.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.7% and EPS at +3.6%, with operating margin around -1329.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +0.0% | -7.0% | -25.5% |
2026 Mar 5, 2026 | +15.2% | +6.4% | +10.5% | +13.5% |
2025 Nov 12, 2025 | +16.7% | -12.2% | -19.5% | -17.7% |
Benchmark Edge
CRBU vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRBU
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRBU Max Drawdown
-51.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CRBU and SPY.
Company Overview
Caribou Biosciences, Inc.
NASDAQ
Caribou Biosciences Inc. is at the forefront of biotechnology, specializing in genome-editing technologies. This company primarily focuses on developing novel therapeutic solutions by leveraging CRISPR-derived gene-editing platforms. With its innovative approach, Caribou aims to address critical challenges in disease treatment, particularly in areas such as oncology and immunology. The company's pioneering work in advancing genetic therapies highlights its pivotal role in the rapidly evolving biotech sector. Caribou Biosciences collaborates with academic institutions and industry leaders to translate complex genomic research into tangible medical therapies, fostering advancements in personalized medicine. The company's deep commitment to scientific excellence propels its influence in the gene-editing landscape, highlighting its importance in the nascent yet potent therapeutic area of genome manipulation. By steering the development of cutting-edge gene-editing applications, Caribou Biosciences is instrumental in shaping the future of bioengineering and therapeutic interventions.
- Leadership
- Dr. Rachel E. Haurwitz Ph.D.
- Employees
- 97
- Street Address
- 2929 7th Street, Suite 105
- Mailing
- Berkeley, CA, 94710
- Region
- Berkeley, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 16.8
- Price/Book
- 1.5
Growth
- Revenue
- +11.7%
- EPS
- +3.6%
- Free Cash Flow
- +22.4%
Profitability
- Gross Margin
- 88.2%
- Operating Margin
- -1329.4%
- Net Margin
- -1327.4%
- ROE
- -91.5%
- ROIC
- -95.1%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 5.71
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.